W celu świadczenia usług na najwyższym poziomie stosujemy pliki cookies. Korzystanie z naszej witryny oznacza, że będą one zamieszczane w Państwa urządzeniu. W każdym momencie można dokonać zmiany ustawień Państwa przeglądarki. Zobacz politykę Cookies

X

Opinion of the Transparency Council

08 August, 2024

Opinion of the Transparency Council – active substance sulfasalazinum

08 August, 2024

Opinion of the Transparency Council – active substance octreotidum

08 August, 2024

Opinion of the Transparency Council – active substance lanreotidum

01 August, 2024

Opinion of the Transparency Council – doxazosinum (4mg)

01 August, 2024

Opinion of the Transparency Council – doxazosinum (1 mg, 2 mg)

01 August, 2024

Opinion of the Transparency Council – valgancyclovir

01 August, 2024

Opinion of the Transparency Council – tocilizumab

01 August, 2024

Opinion of the Transparency Council – rituximab

25 July, 2024

Opinion of the Transparency Council – Future without diabetes

25 July, 2024

Opinion of the Transparency Council – Program for prevention and early detection of eye defects in children aged 14 years residing in the municipality of Opalenica for 2024-2026

25 July, 2024

Opinion of the Transparency Council – Prevention and early detection of testicular cancer among men aged 20-39 years, residing in the Wielkopolska province for 2024-2025

18 July, 2024

Opinion of the Transparency Council – filgrastym

04 July, 2024

Opinion of the Transparency Council – diazepamum

27 June, 2024

Opinion of the Transparency Council – propranolol

27 June, 2024

Opinion of the Transparency Council – atorvastatinum, lovastatinum, simvastatinum

27 June, 2024

Opinion of the Transparency Council – Breast cancer prevention program for women residing in the Municipality of Tczew for the years 2024-2025

27 June, 2024

Opinion of the Transparency Council – Program of early detection of breast cancer among female residents of Olesnica for the year 2024

20 June, 2024

Opinion of the Transparency Council – prednisonum

20 June, 2024

Opinion of the Transparency Council – salbutamolum

20 June, 2024

Opinion of the Transparency Council – amantadine

15 September, 2022

Opinion of the Transparency Council – sirolimus

16 August, 2022

Opinion of the Transparency Council – health policy programme on infertility treatment (Rzeszów)

16 August, 2022

Opinion of the Transparency Council – health policy programme on breast cancer (Municipality of Toszek)

16 August, 2022

Opinion of the Transparency Council – changes to the drug programme B.82

Home page

News Publications Publikacje BIP

#webinar agenda Aktualności announcement of the President azathioprinum Bimzelx Collegium AOTMiT colorectal cancer communication Communication from the Transparency Council Communication on the Tariff Council Cost Accounting Standard Council for Tariffs Affairs covering neonatal care cyclophosphamidum Data acquisition dental treatment services diseases of the organ of vision drug programme Empliciti entecavirum etanercept Fycompa gastroscopy glaucoma health policy program health policy programme health policy programme on breast cancer health policy programme on infertility treatment Health Policy Programmes Impavido in vitro Inovelon Jardiance Meeting of the Transparency Council methotrexatum Milupa Basic-P minimum wage increases mycophenolate mofetil new new tariffs news Notice Notice of the President Ontozry Onureg Opdivo Opdivo (nivolumab)opinion Opinion of the President Opinion of the Transparency Council Ospolot Ozurdex perinatal care Ponvory Position of the Transparency Council Press conference Recommendation Recommendation of the President Renastep report Rezurock sirolimus Suliqua Tariff Council Tariffs Council Tarification Plan 2025 tenofovirum disoproxilum the drug programme B.44 the drug programme B.82 The Meeting of the Tariffs Council trainings Transparency Council Tremfya update Vivitrol Yervoy

Pokaż więcej ↓

Pokaż mniej ↑